Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R N JONES

Showing results (681-690 of 818) with videos related to

Pageof 82
Sort By:
Infection Control and Hospital Epidemiology|June 1, 1994
Nosocomial transmission of Serratia odorifera biogroup. 2: Case report demonstration by macrorestriction analysis of chromosomal DNA using pulsed-field gel electrophoresisH S Sader, T M Perl, R J Hollis, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 18, 2003
Resistance to beta-lactams among blood isolates of Salmonella spp. in European hospitals: results from the SENTRY Antimicrobial Surveillance Program 1997-98L S Tzouvelekis, V Lukova, P T Tassios, et al.
British Journal of Industrial Medicine|November 1, 1979
Mill effect and dose-response relationships in byssinosisR N Jones, J E Diem, H Glindmeyer, et al.
Journal of Clinical Microbiology|January 1, 1989
Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory StandardsA L Barry, P C Fuchs, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1986
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolatesP C Fuchs, R N Jones, A L Barry, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 1999
Nosocomial bloodstream infections in United States hospitals: a three-year analysisM B Edmond, S E Wallace, D K McClish, et al.
Antimicrobial Agents and Chemotherapy|April 2, 1999
Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centersD J Diekema, S L Coffman, S A Marshall, et al.
Diagnostic Microbiology and Infectious Disease|April 23, 1999
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study GroupR N Jones, K C Kugler, M E Erwin, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1984
In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centersA L Barry, R N Jones, L W Ayers, et al.
Diagnostic Microbiology and Infectious Disease|February 1, 1993
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivativeW W Hoover, E H Gerlach, D J Hoban, et al.
Pageof 82

Showing results (681-690 of 818) with videos related to

Sort By:
Pageof 82
Infection Control and Hospital Epidemiology|June 1, 1994
Nosocomial transmission of Serratia odorifera biogroup. 2: Case report demonstration by macrorestriction analysis of chromosomal DNA using pulsed-field gel electrophoresisH S Sader, T M Perl, R J Hollis, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 18, 2003
Resistance to beta-lactams among blood isolates of Salmonella spp. in European hospitals: results from the SENTRY Antimicrobial Surveillance Program 1997-98L S Tzouvelekis, V Lukova, P T Tassios, et al.
British Journal of Industrial Medicine|November 1, 1979
Mill effect and dose-response relationships in byssinosisR N Jones, J E Diem, H Glindmeyer, et al.
Journal of Clinical Microbiology|January 1, 1989
Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory StandardsA L Barry, P C Fuchs, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1986
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolatesP C Fuchs, R N Jones, A L Barry, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 1999
Nosocomial bloodstream infections in United States hospitals: a three-year analysisM B Edmond, S E Wallace, D K McClish, et al.
Antimicrobial Agents and Chemotherapy|April 2, 1999
Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centersD J Diekema, S L Coffman, S A Marshall, et al.
Diagnostic Microbiology and Infectious Disease|April 23, 1999
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study GroupR N Jones, K C Kugler, M E Erwin, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1984
In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centersA L Barry, R N Jones, L W Ayers, et al.
Diagnostic Microbiology and Infectious Disease|February 1, 1993
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivativeW W Hoover, E H Gerlach, D J Hoban, et al.
Pageof 82